A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 microg/160 microg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 microg/500 microg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Sponsors Novartis

Most Recent Events

27 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
14 Jun 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
11 Feb 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight